Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 83 articles:
HTML format

Single Articles

    August 2022
  1. XING P, Jiang Z, Liu Y
    Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
    BMC Cancer. 2022;22:926.
    PubMed     Abstract available

    July 2022
  2. LIN Q, Pei L, Zhao Z, Zhuang X, et al
    Glycoprotein alpha-Subunit of Glucosidase II (GIIalpha) is a novel prognostic biomarker correlated with unfavorable outcome of urothelial carcinoma.
    BMC Cancer. 2022;22:817.
    PubMed     Abstract available

  3. MIYAI K, Kawamura K, Ito K, Matsukuma S, et al
    Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma.
    BMC Cancer. 2022;22:787.
    PubMed     Abstract available

  4. KIM GT, Kim EY, Shin SH, Lee H, et al
    Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma.
    BMC Cancer. 2022;22:727.
    PubMed     Abstract available

    June 2022
  5. HOU J, Lu Z, Cheng X, Dong R, et al
    Ferroptosis-related long non-coding RNA signature predicts the prognosis of bladder cancer.
    BMC Cancer. 2022;22:719.
    PubMed     Abstract available

  6. LI JD, Farah AA, Huang ZG, Zhai GQ, et al
    Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
    BMC Cancer. 2022;22:713.
    PubMed     Abstract available

  7. ZHANG Q, Zhang W, Lin T, Lu W, et al
    Mass cytometry reveals immune atlas of urothelial carcinoma.
    BMC Cancer. 2022;22:677.
    PubMed     Abstract available

  8. JIANG L, Chen S, Pan Q, Zheng J, et al
    The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.
    BMC Cancer. 2022;22:676.
    PubMed     Abstract available

  9. JEONG SH, Han JH, Jeong CW, Kim HH, et al
    Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor.
    BMC Cancer. 2022;22:631.
    PubMed     Abstract available

    May 2022
  10. HAO N, Yang D, Liu T, Liu S, et al
    Laminin-integrin a6b4 interaction activates notch signaling to facilitate bladder cancer development.
    BMC Cancer. 2022;22:558.
    PubMed     Abstract available

  11. ZHU L, Liu X, Zhang W, Hu H, et al
    MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.
    BMC Cancer. 2022;22:556.
    PubMed     Abstract available

  12. DENG L, Chao H, Deng H, Yu Z, et al
    A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer.
    BMC Cancer. 2022;22:510.
    PubMed     Abstract available

  13. WEICKHARDT AJ, Lau DK, Hodgson-Garms M, Lavis A, et al
    Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
    BMC Cancer. 2022;22:478.
    PubMed     Abstract available

    April 2022
  14. YANG Z, Zhang X, Zhang J, Gao J, et al
    Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT
    BMC Cancer. 2022;22:462.
    PubMed     Abstract available

  15. FANG C, Huang X, Dai J, He W, et al
    The circular RNA circFARSA sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.
    BMC Cancer. 2022;22:373.
    PubMed     Abstract available

    March 2022
  16. WU Z, Xia C, Zhang C, Yang D, et al
    Prognostic significance of SNCA and its methylation in bladder cancer.
    BMC Cancer. 2022;22:330.
    PubMed     Abstract available

  17. BHATTACHARJEE S, Sullivan MJ, Wynn RR, Demagall A, et al
    PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth.
    BMC Cancer. 2022;22:312.
    PubMed     Abstract available

  18. SUN M, Liu X, Zhao W, Zhang B, et al
    Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p.
    BMC Cancer. 2022;22:313.
    PubMed     Abstract available

  19. GUAN Z, Sun Y, Mu L, Jiang Y, et al
    Tenascin-C promotes bladder cancer progression and its action depends on syndecan-4 and involves NF-kappaB signaling activation.
    BMC Cancer. 2022;22:240.
    PubMed     Abstract available

  20. FANG Q, Zhang X, Nie Q, Hu J, et al
    Improved urine DNA methylation panel for early bladder cancer detection.
    BMC Cancer. 2022;22:237.
    PubMed     Abstract available

    February 2022
  21. WANG R, Kang H, Zhang X, Nie Q, et al
    Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
    BMC Cancer. 2022;22:214.
    PubMed     Abstract available

  22. KIM KS, Kim SH, Cho HJ, Sur HJ, et al
    Holmium laser-assisted laparoscopic partial cystectomy for bladder cancer: a single-institutional pilot study with technical feasibility and short-term oncological outcome.
    BMC Cancer. 2022;22:195.
    PubMed     Abstract available

  23. WAHLIN S, Boman K, Moran B, Nodin B, et al
    Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
    BMC Cancer. 2022;22:131.
    PubMed     Abstract available

    January 2022
  24. HUANG T, Li J, Wang SM
    Core promoter mutation contributes to abnormal gene expression in bladder cancer.
    BMC Cancer. 2022;22:68.
    PubMed     Abstract available

  25. ZHANG Y, Zhu B, Cai Y, Zhu S, et al
    Alteration in glycolytic/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration.
    BMC Cancer. 2022;22:2.
    PubMed     Abstract available

    December 2021
  26. LIN H, Shi X, Li H, Hui J, et al
    Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer.
    BMC Cancer. 2021;21:1293.
    PubMed     Abstract available

  27. MARTINEZ CHANZA N, Soukane L, Barthelemy P, Carnot A, et al
    Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
    BMC Cancer. 2021;21:1292.
    PubMed     Abstract available

    November 2021
  28. SMITH V, Mukherjee D, Lunj S, Choudhury A, et al
    The effect of hypoxia on PD-L1 expression in bladder cancer.
    BMC Cancer. 2021;21:1271.
    PubMed     Abstract available

  29. LI X, Fu S, Huang Y, Luan T, et al
    Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer.
    BMC Cancer. 2021;21:1267.
    PubMed     Abstract available

  30. MA T, Wang X, Meng L, Liu X, et al
    An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    BMC Cancer. 2021;21:1256.
    PubMed     Abstract available

  31. FUKUHARA H, Nohara T, Nishimoto K, Hatakeyama Y, et al
    Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study.
    BMC Cancer. 2021;21:1223.
    PubMed     Abstract available

    October 2021
  32. HINSENVELD FJ, Noordman BJ, Boormans JL, Voortman J, et al
    Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    BMC Cancer. 2021;21:1161.
    PubMed     Abstract available

  33. ZHEN H, Du P, Yi Q, Tang X, et al
    LINC00958 promotes bladder cancer carcinogenesis by targeting miR-490-3p and AURKA.
    BMC Cancer. 2021;21:1145.
    PubMed     Abstract available

  34. VERGHOTE F, Poppe L, Verbeke S, Dirix P, et al
    Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    BMC Cancer. 2021;21:1113.
    PubMed     Abstract available

    September 2021
  35. WANG M, Ren X, Wang G, Sun X, et al
    Construction of a survival prediction model for high-and low -grade UTUC after tumor resection based on "SEER database": a multicenter study.
    BMC Cancer. 2021;21:999.
    PubMed     Abstract available

  36. COLLING R, Colling H, Browning L, Verrill C, et al
    Validation of grading of non-invasive urothelial carcinoma by digital pathology for routine diagnosis.
    BMC Cancer. 2021;21:995.
    PubMed     Abstract available

    August 2021
  37. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Correction to: Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:956.

  38. LIANG Y, Ye F, Xu C, Zou L, et al
    A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer.
    BMC Cancer. 2021;21:943.
    PubMed     Abstract available

  39. WANG X, Guo J, Wang L, Wang M, et al
    Modified completely intrafascial radical cysprostatectomy for bladder cancer: a single-center, blinded, controlled study.
    BMC Cancer. 2021;21:887.
    PubMed     Abstract available

    July 2021
  40. LI J, Cao J, Li P, Yao Z, et al
    Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    BMC Cancer. 2021;21:858.
    PubMed     Abstract available

  41. TANG X, Qian WL, Yan WF, Pang T, et al
    Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study.
    BMC Cancer. 2021;21:823.
    PubMed     Abstract available

  42. FU Y, Sun S, Bi J, Kong C, et al
    A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer.
    BMC Cancer. 2021;21:810.
    PubMed     Abstract available

    June 2021
  43. WANG Z, Tu L, Chen M, Tong S, et al
    Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    BMC Cancer. 2021;21:692.
    PubMed     Abstract available

  44. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:676.
    PubMed     Abstract available

    May 2021
  45. LYU X, Wang P, Qiao Q, Jiang Y, et al
    Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    BMC Cancer. 2021;21:646.
    PubMed     Abstract available

  46. CHEN X, Lin X, Pang G, Deng J, et al
    Significance of KDM6A mutation in bladder cancer immune escape.
    BMC Cancer. 2021;21:635.
    PubMed     Abstract available

  47. CHAN LC, Kalyanasundram J, Leong SW, Masarudin MJ, et al
    Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes.
    BMC Cancer. 2021;21:625.
    PubMed     Abstract available

  48. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor.
    BMC Cancer. 2021;21:604.
    PubMed     Abstract available

  49. GRIVAS P, Loriot Y, Morales-Barrera R, Teo MY, et al
    Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
    BMC Cancer. 2021;21:593.
    PubMed     Abstract available

  50. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed     Abstract available

    April 2021
  51. ZHANG Z, Yu Y, Zhang P, Ma G, et al
    Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    BMC Cancer. 2021;21:458.
    PubMed     Abstract available

  52. MANZANO RG, Catalan-Latorre A, Brugarolas A
    RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    BMC Cancer. 2021;21:432.
    PubMed     Abstract available

    March 2021
  53. MIYAKE M, Iida K, Nishimura N, Miyamoto T, et al
    Non-maintenance intravesical Bacillus Calmette-Guerin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
    BMC Cancer. 2021;21:266.
    PubMed     Abstract available

  54. CHEN F, Wang Q, Zhou Y
    The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
    BMC Cancer. 2021;21:244.
    PubMed     Abstract available

    February 2021
  55. YANG B, Zhao X, Wan C, Ma X, et al
    Genomic profiling of Chinese patients with urothelial carcinoma.
    BMC Cancer. 2021;21:162.
    PubMed     Abstract available

    January 2021
  56. YONEYAMA T, Hatakeyama S, Sutoh Yoneyama M, Yoshiya T, et al
    Tumor vasculature-targeted (10)B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy.
    BMC Cancer. 2021;21:72.
    PubMed     Abstract available

  57. PORRECA A, Palmer K, Artibani W, Antonelli A, et al
    Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer.
    BMC Cancer. 2021;21:51.
    PubMed     Abstract available

  58. OKAMURA S, Yoshino H, Kuroshima K, Tsuruda M, et al
    EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
    BMC Cancer. 2021;21:48.
    PubMed     Abstract available

    December 2020
  59. KIM TM, Yoo JS, Moon HW, Hur KJ, et al
    Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up.
    BMC Cancer. 2020;20:1203.
    PubMed     Abstract available

  60. JOHN A, Gunes C, Bolenz C, Vidal-Y-Sy S, et al
    Bladder cancer-derived interleukin-1 converts the vascular endothelium into a pro-inflammatory and pro-coagulatory surface.
    BMC Cancer. 2020;20:1178.
    PubMed     Abstract available

    November 2020
  61. ZHAI M, Tang C, Li M, Chen X, et al
    Short-term mortality risks among patients with non-metastatic bladder cancer.
    BMC Cancer. 2020;20:1148.
    PubMed     Abstract available

    October 2020
  62. LIU B, Sun W, Gao W, Li L, et al
    microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis.
    BMC Cancer. 2020;20:1019.
    PubMed     Abstract available

    September 2020
  63. KOTECHA P, Moss CL, Enting D, Gillett C, et al
    Cohort profile: King's Health Partners bladder cancer biobank.
    BMC Cancer. 2020;20:920.
    PubMed     Abstract available

  64. MATHEUS LHG, Dalmazzo SV, Brito RBO, Pereira LA, et al
    1-Methyl-D-tryptophan activates aryl hydrocarbon receptor, a pathway associated with bladder cancer progression.
    BMC Cancer. 2020;20:869.
    PubMed     Abstract available

  65. TIAN Z, Meng L, Wang X, Diao T, et al
    Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma.
    BMC Cancer. 2020;20:851.
    PubMed     Abstract available

    August 2020
  66. PORSERUD A, Karlsson P, Rydwik E, Aly M, et al
    The CanMoRe trial - evaluating the effects of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer: the study protocol of a randomised controlled trial.
    BMC Cancer. 2020;20:805.
    PubMed     Abstract available

  67. JAMIESON L, Forster MD, Zaki K, Mithra S, et al
    Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    BMC Cancer. 2020;20:743.
    PubMed     Abstract available

    June 2020
  68. MAKELA R, Arjonen A, Harma V, Rintanen N, et al
    Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
    BMC Cancer. 2020;20:590.
    PubMed     Abstract available

    May 2020
  69. RIPPING TM, Kiemeney LA, van Hoogstraten LMC, Witjes JA, et al
    Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB).
    BMC Cancer. 2020;20:455.
    PubMed     Abstract available

    March 2020
  70. ZHANG Y, Ou DH, Zhuang DW, Zheng ZF, et al
    In silico analysis of the immune microenvironment in bladder cancer.
    BMC Cancer. 2020;20:265.
    PubMed     Abstract available

  71. PARKER HG, Dhawan D, Harris AC, Ramos-Vara JA, et al
    RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors.
    BMC Cancer. 2020;20:251.
    PubMed     Abstract available

  72. MORSCH R, Rose M, Maurer A, Cassataro MA, et al
    Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
    BMC Cancer. 2020;20:230.
    PubMed     Abstract available

  73. LATIFOVIC L, Villeneuve PJ, Parent ME, Kachuri L, et al
    Silica and asbestos exposure at work and the risk of bladder cancer in Canadian men: a population-based case-control study.
    BMC Cancer. 2020;20:171.
    PubMed     Abstract available

    February 2020
  74. HUPE MC, Dormayer L, Ozimek T, Struck JP, et al
    Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer.
    BMC Cancer. 2020;20:140.
    PubMed     Abstract available

    January 2020
  75. SCHMID SC, Koll FJ, Rodel C, Maisch P, et al
    Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT).
    BMC Cancer. 2020;20:8.
    PubMed     Abstract available

    December 2019
  76. WANG Z, Liu X, Liu X, Sun H, et al
    UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
    BMC Cancer. 2019;19:1195.
    PubMed     Abstract available

    November 2019
  77. BOURN J, Rathore K, Donnell R, White W, et al
    Detection of carcinogen-induced bladder cancer by fluorocoxib A.
    BMC Cancer. 2019;19:1152.
    PubMed     Abstract available

  78. MOLENAAR RJ, van Hattum JW, Brummelhuis IS, Oddens JR, et al
    Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer.
    BMC Cancer. 2019;19:1133.
    PubMed     Abstract available

  79. ZHANG J, Wang Y, Weng H, Wang D, et al
    Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations.
    BMC Cancer. 2019;19:1054.
    PubMed     Abstract available

    October 2019
  80. ALBARAKATI N, Khayyat D, Dallol A, Al-Maghrabi J, et al
    The prognostic impact of GSTM1/GSTP1 genetic variants in bladder Cancer.
    BMC Cancer. 2019;19:991.
    PubMed     Abstract available

    August 2019
  81. SASSENBERG M, Droop J, Schulz WA, Dietrich D, et al
    Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.
    BMC Cancer. 2019;19:806.
    PubMed     Abstract available

  82. FIORENTINO V, Pierconti F, Lenci N, Calicchia M, et al
    Urinary bladder leiomyosarcoma with osteoclast-like multinucleated giant cells: a case report.
    BMC Cancer. 2019;19:763.
    PubMed     Abstract available

    June 2019
  83. ZENG S, Liu A, Dai L, Yu X, et al
    Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms.
    BMC Cancer. 2019;19:604.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.